We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byAnnika Hulin
Modified over 2 years ago
gefitinib EGFR inhibitor Non-small cell lung cancer Rash & diarrhea
erlotinib EGFR inhibitor non-small cell lung cancer & pancreatic carcinoma (better than gefitinib) Rash& diarrhea
Cetuximab EGFR antibody Colorectal cancer & head and neck cancer Rash & diarrhea
trastuzumab (aka herceptin) EGFR antibody Breast cancer or metastatic gastric cancer w/HER2 expression cardiotoxicity
imatinib Inhibitor of BCR-ABL, C-KIT, and PDGFR CML, GI stromal tumor expressing KIT, idiopathic hypereosinophilic syndrome
Sorafenib Inhibitor of B-RAF Renal cell carcinoma & hepatocellular carcinoma
Rapamycin (sirolimus) mTOR inhibitor Rejection prophylaxis for renal transplant
Bortezomib Inhibits 20S subunit of proteasome Multiple myeloma & mantle cell lymphoma
Bevacizumab VEGF/VEGFR antibody Metastatic colorectal cancer & NSCLC Contraindicated for cerebrally metastasized NSCLC
sunitinib VEGF/VEGFR inhibitor Renal cell carcinoma & GI stromal tumor
thalidomide Inhibits TNF-a and bFGF Multiple myeloma & erythema nodosum leprosum Beware thrombosis
lenalidomide Inhibits TNF-a and bFGF (better than thal.) Multiple myeloma & myelodysplastic syndrome Lesser risk of thrombosis than thalidomide
rituximab CD-20 antibody B cell non-hodgkin lymphoma Beware immunosuppression
Therapy Targeted د. نورس نبيل جعفر أخصائية في علم الأورام طبيبة مشرفة بمشفى ابن النفيس مؤتمر نقابة أطباء سورية العلمي الأول.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 102 Anticancer Drugs II: Hormonal Agents, Biologic Response.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
Targeted Therapies - little & large explained Chris Clarke Macmillan Lead Pharmacist LNR Cancer Network.
Special Topics Cancer Pharmacology II Joseph De Soto MD, PhD, FAIC.
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
Anticancer drugs Specific tumor-targeted therapy, Immunomodulators, Anticancer Vaccines.
Chapter Plant products 抗肿瘤植物药. Chapter Plant products Paclitaxel (Taxol) 紫杉醇.
Oral Cancer Early diagnostic and Treatment
Biological and Molecular Targeted Therapy for HHC
Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.
Cytidine analogue ALL, AML
Encompass how some hormones and antihormones are utilized as anticancer therapy Identify concept of immunomodulation as an anticancer treatment modality.
Basic Science of Surgical Oncology Sharmila Roy-Chowdhury, M.D. Assistant Professor Division of Surgical Oncology.
Biotechnology in Fighting Fatal Disease – Cancer National Biotechnology Symposium 2012 Innovations in Biotechnology: From Education to Industry Sep 1,
TARGETED CANCER THERAPY IN 2016: WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEEDS TO KNOW (SUPPLEMENTARY SLIDES) Steven J. Kussick, MD, PhD Associate.
DNA diagnosis of lung cancer
Sarah Cannon Research Institute ASCO Presentation Summary.
NEW WEAPONS IN THE WAR OF CANCER Lodovico Balducci M.D. H. Lee Moffitt Cancer Center Tampa, Florida.
Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.
Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.
Tyrosine Kinase Inhibitors PHL 425 Dr. Mohamed M. Sayed-AShmed.
ANTICANCER DRUGS DR FATAI OLUYADI USMLEINCLINED.COM 1.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Nitrogen mustards: mustard gas used first during WWI. Leukopenia and GI ulceration noted in survivors Bondage: crosslinking agents.
Presented by : PharmD Group 5 Supervised by : Dr. Nashaat Lotfy.
Figure 16.45a The Biology of Cancer (© Garland Science 2007)
GENE EXPRESSION PROFILING IN BREAST CARCINOMA Dr Partha Ghosh 2 nd year PGT, General Surgery N.R.S Medical college.
Targeted Therapy in Hematology Dieter Hoelzer – Frankfurt am Main Christoph Zielinski – Vienna, Austria Hans-Joachim Schmoll – Halle, Germany Richard Greil.
New Technologies and Challenges Targeted Therapies in Cancer New Technologies and Challenges Targeted Therapies in Cancer Ian Olver MD PhD CEO The Cancer.
Targeted Therapy for Renal Cell Cancer Dr.MahmoodzadehOncologist-Hematologist.
Approaching Personalized Oncology as a Clinician and Researcher Where are we now, and how can we take it further? Andrew Poklepovic MD Massey Cancer Center.
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA.
Pancreatic NET What’s new? George Fisher, MD PhD Pamela Kunz, MD Division of Oncology Stanford University Medical School March 29, 2009.
From the Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston; and the Department of Internal Medicine III, University.
Adaptive Population Enrichment for Oncology Trials with Time to Event Endpoints Cyrus Mehta, Ph.D. President, Cytel Inc.
HEPATOCELLULAR CARCINOMA Manal Abdel Hamid Associate Prof. Of medical oncology.
1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.
Also known as lymphoplasmacytic lymphoma A rare type of non-Hodgkin lymphoma WM affects lymphoplasmacytic (LPL) Cells B-Cells LPL Cells Plasma Cells Abs.
Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.
LV dysfunction Vasospasm and ischemia Hypertension VTE Conduction disease Arrhythmias.
CANCER, ONCOGENES AND TUMOUR SUPPRESSOR GENES PHL 425 Dr. Mohamed M. Sayed-Ahmed 1/1/2015.
A daganat-terápia alapjai Diagnosis –Histopathology –Tumor markers Cell surface markers (CD20, CD34…) Genetic markers (BRCA-1,Philadelphia chromosome)
Cancer, Oncogenes and Tumour suppressor Genes 1 Dr. Mohamed M. Sayed-Ahmed.
In humans, billions of cells die each day Cells die in two ways: 1.Necrosis 2.Apoptosis.
Horizon scanning for managing medicines Produced by UKMi to support the Prescribing Outlook series November 2007.
Integrating Research and Clinical Practice Jim Koeller, M.S. Professor University of Texas at Austin & the Health Science Center, San Antonio, USA.
Prince of Wales clinical school and Lowy cancer research centre Future challenges to HTA Policy challenges.
Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:
FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,
© 2017 SlidePlayer.com Inc. All rights reserved.